The Survivorship Bias After the Pandemic: The Suite Spot

The Suite Spot is a fireside chat about all topics IT and OT. We will attempt to bring clarity to the business value of traditionally tech topics. We remove the fog of acronym war and deliver to you the value you need to make these complex technologies work for your business.

Powered by RedCircle

Carlos Vargas, host of The Suite Spot, was joined with co-hosts Howard Holton and Paul Lewis in a discussion on business outcomes and capabilities.  Holton and Lewis shared their experiences and insights on how IT providers can be successful and why others struggle or fail.

Vargas kicked off the discussion with questions, “Outcomes versus capabilities: How does a leader see that?  What does that mean?”

Holton and Lewis explained that it is of foremost importance to start with the reasons why customers are looking for IT solutions.  “We are trying to solve a problem.”  They expand with examples that show that sometimes customers don’t fully understand the reasons how planning a robust solution requires a deep understanding of the root causes for the IT solution request in the first place.

Taking this approach enables the creation of a holistic solution that leads to a strong business relationship.  They identify that vendor selection is a pain-point for customers and can be extremely costly in both time and money.  As the hosts discuss, a cohesive IT solution leads to becoming the most trusted vendor that customers reach out to when looking to solve future problems.

Make Sure to Subscribe to The Suite Spot to Stay Up to Date!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More